Valuation
- Market cap
- 7,952,000
- Revenue TTM
- $5,920,000
- Net income TTM
- $25,210,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 425.84%
- Debt to equity
- 0.00
Trading
- Volume
- 150,779
- Avg volume
- 177,048
- Day's range
- $0.02 – $0.03
- Shares out
- 265,052,000
- Stochastic %K
- 43%
- Beta
- 0.75
- Analysts
- Hold
- Price target
- $1.00
Company profile
Adaptimmune Therapeutics plc engages in research, development, and subsequent manufacture and commercialisation of cell therapies to treat cancer in the United States and the United Kingdom. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- https://www.adaptimmune.com
- Address
- The Innovation Centre, 99 Park Drive, Milton Park, Abingdon, United Kingdom
Latest news
No headlines yet.
